Navigation Links
Amgen And Servier Announce Product Collaboration
Date:7/9/2013

and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to Amgen's business. Unless otherwise noted, Amgen is providing this information as of July 9, 2013, and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with Amgen's products after they are on the market. Amgen's business may be impacted by government investigations, litigation and
'/>"/>

SOURCE Amgen; Servier
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
2. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
3. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
4. Amgen Announces 2013 Second Quarter Dividend
5. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
6. Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
7. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
8. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
9. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
10. Amgen Announces 2012 Third Quarter Dividend
11. Amgen to Present at the Leerink Swann Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Mass. , July 30, 2014  Decision ... pharmacy and medical directors in the ... drivers of biosimilar market penetration will be the ... organizations (MCOs) and the expected lower cost to ... for biosimilars that meet their pricing expectations in ...
(Date:7/30/2014)... 30, 2014 While administrative claims ... services research for a relatively long period of ... regarding the use of these ‘big data’ for ... By combining today’s powerful computer technology with the ... ‘big data’ holds significant promise for identifying optimal ...
(Date:7/30/2014)... July 30, 2014 With the ... of personal health expenditure as well as the ... system, China diagnostic reagent industry has been developing ... 90%. In 2013, Chinese in vitro diagnostics market ... came from in vitro diagnostic reagents. , ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Yuma ... facility and complementary therapies brings comprehensive cancer care ... state-of-the-art Yuma Regional Cancer Center has officially opened. ... the program includes services such as open, semi-private ... therapy, American Cancer Society Resource Center, hematology, rehabilitation ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2
... Pasteuria Bioscience announced that it has received registration ... Pasteuria usgae . This is a critical step towards ... bacteria prevalent in soil that have long been recognized as ... , "We,re very pleased to receive this EPA registration," ...
... STOCKHOLM, June 8 Diamyd Medical reported today,that the company ... to include children with type 1 diabetes from 10 years,of ... vaccine Diamyd(R). , (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ... conducting two parallel phase III studies, one in,Europe and one ...
... Through One Year , , HERZLIYA, Israel and SKILLMAN, ... U.S. Food and Drug Administration (FDA) approved a labeling supplement ... EVOLENCE(R), a collagen-based dermal filler for the correction of moderate ... , , To view the Multimedia News Release, go ...
Cached Biology Technology:Pasteuria Bioscience Receives EPA Registration for Nematode Control 2Diamyd(R) Phase III Study Approved for Younger Patients in the US 2Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 2Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 3Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 4
(Date:7/30/2014)... scientists unveiled the first high-resolution map of the ... country of Per. The new and improved methodology ... change for future market-based carbon economies. The ... ecological diversity and it provides the critical input ... conservation, land use, and enforcement purposes. The technique ...
(Date:7/29/2014)... of Bristol,s Nutrition and Behaviour Unit (NBU) has looked ... planning meals. , The research, to be presented at ... (SSIB 2014) in Seattle, USA this week [29 July ... team was led by Professor Jeff Brunstrom, and is ... part of a Biotechnology and Biological Sciences Research Council ...
(Date:7/29/2014)... the climate warms and sea ice retreats, the North ... of increasingly open water which is predicted to extend ... this century. Storms thus have the potential to create ... new and unpredictable element to the region. , A University ... in the middle of the Arctic Ocean, and detected ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3Huge waves measured for first time in Arctic Ocean 2Huge waves measured for first time in Arctic Ocean 3
... engineers at Purdue University have developed a new method ... and they are proposing the creation of mobile processing ... fuels. "What,s important is that you can ... chips, switch grass, corn stover, rice husks, wheat straw ...
... tract is a teeming mass of hundreds of types of ... help us digest food and keep bad bacteria in check. ... receptor is a key player amid the gut bacteria ... helping to govern their activity, responding to their cues, and ...
... calling on policymakers to encourage the transition from coal-based electricity ... carbon tax. Such a mechanism would help limit carbon ... Change Conference in Copenhagen last December, the United States pledged ... by 17 percent by 2020. Dagobert Brito, the ...
Cached Biology News:New biofuels processing method for mobile facilities 2New biofuels processing method for mobile facilities 3Amid the murk of 'gut flora,' vitamin D receptor emerges as a key player 2Amid the murk of 'gut flora,' vitamin D receptor emerges as a key player 3Researchers calculate the cost of CO2 emissions, call for carbon tax 2
... (1995) This volume provides excellent ... for the study of major HIV proteins ... ribonuclease H, integrase and protease. Expression of ... Tat and Rev assays; HIV/CD4 interactions; transient ...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Tachykinin (H-2)...
Human GATA-2 Affinity Purified Polyclonal Ab...
Biology Products: